eCite Digital Repository
P43 The economic burden of idiopathic pulmonary fibrosis in Australia
Cox, I and de Graaff, B and Ahmad, H and Campbell, JA and Otahal, P and Corte, TJ and Walter, HE and Palmer, AJ, P43 The economic burden of idiopathic pulmonary fibrosis in Australia, The Future of HEOR in Patient-Driven Digital Healthcare Systems, 15-18 May 2022, Washington D.C, pp. S296. ISSN 1524-4733 (2022) [Conference Extract]
Pending copyright assessment - Request a copy
Background: Idiopathic pulmonary fibrosis (IPF) is form of interstitial lung disease which generally occurs in persons 60 years and older.It is characterised by a high symptom burden, and frequent encounters with health services. This study aimed to determine the economic burden of IPF in Australia with a focus on resource utilisation and associated direct costs.
Methods: Participants were recruited from the Australian IPF Registry (AIPFR) between August 2018 and December 2019. Data on resource utilisation and costs were collected via cost diaries and linked administrative data. Clinical data were collected from the AIPFR. Costing was performed from a partial societal perspective and a "bottom up" costing methodology was utilized focusing on direct medical and non-medical costs. Costs were standardized to 2021 Australian dollars ($).
Results: The average annual total direct costs per person with IPF was $31,655 (95% confidence interval: $27,723-$35,757). Extrapolating costs based on prevalence estimates, the total annual costs in Australia are projected to be $299 million (95% confidence interval: $262 million -$338 million) which is based on published prevalence for IPF. Costs were mainly driven by antifibrotic medication, hospital admissions and medications for comorbidities. Disease severity, comorbidities and antifibrotic medication all had varying impacts on resource utilisation and costs.
Conclusions: This study provides the first comprehensive analysis of IPF-related direct costs in Australia, identifies the key cost drivers and provides a framework for future health economic analyses. Additionally, it provided insight into the major cost drivers which include antifibrotic medication, hospital admissions and medications related to comorbidities. Our findings emphasise the importance of the appropriate management of comorbidities in the care of people with IPF as this was one of the main reasons for hospitalisations.
|Item Type:||Conference Extract|
|Keywords:||idiopathic pulmonary fibrosis, respiratory disease, cost of illness, economic burden|
|Research Group:||Applied economics|
|Research Field:||Health economics|
|Objective Group:||Public health (excl. specific population health)|
|Objective Field:||Public health (excl. specific population health) not elsewhere classified|
|UTAS Author:||Cox, I (Dr Ingrid Cox)|
|UTAS Author:||de Graaff, B (Dr Barbara de Graaff)|
|UTAS Author:||Ahmad, H (Dr Hasnat Ahmad)|
|UTAS Author:||Campbell, JA (Dr Julie Campbell)|
|UTAS Author:||Otahal, P (Mr Petr Otahal)|
|UTAS Author:||Walter, HE (Professor Haydn Walters)|
|UTAS Author:||Palmer, AJ (Professor Andrew Palmer)|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page